Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial

耐受性 临床终点 医学 养生 临床研究阶段 临床试验 肿瘤科 内科学 胃肠病学 外科 不利影响
作者
Shuiling Jin,Ruihua Zhao,Chuang Zhou,Qian Zhong,Jianxiang Shi,Chang Su,Qinglong Li,Xiaoxing Su,Huabin Chi,Xu Lu,Guozhong Jiang,Renyin Chen,Jinming Han,Miao Jiang,Shishi Qiao,Jingjing Liu,Min Seob Song,Lijie Song,Yabing Du,Zhiwei Chang
出处
期刊:International Journal of Cancer [Wiley]
卷期号:152 (8): 1648-1658 被引量:31
标识
DOI:10.1002/ijc.34372
摘要

Patients with biliary tract cancer (BTC) were associated with poor prognosis and limited therapeutic options after first-line therapy currently. In this study, we sought to evaluate the feasibility and tolerability of sintilimab plus anlotinib as the second-line treatment for patients with advanced BTC. Eligible patients had histologically confirmed locally advanced unresectable or metastatic BTC and failed after the first-line treatment were recruited. The primary endpoint was overall survival (OS). Simultaneously, association between clinical outcomes and genomic profiling and gut microbiome were explored to identify the potential biomarkers for this regimen. Twenty patients were consecutively enrolled and received study therapy. The trail met its primary endpoint with a median OS of 12.3 months (95% CI: 10.1-14.5). Only four (20%) patients were observed of the grade 3 treatment-related adverse events (TRAEs) and no grade 4 or 5 TRAEs were detected. Mutation of AGO2 was correlated with a significantly longer OS. Abundance of Proteobacteria was associated with inferior clinical response. Therefore, sintilimab plus anlotinib demonstrated encouraging anti-tumor activity with a tolerable safety profile and deserved to be investigated in larger randomized trials for patients with advanced BTC subsequently.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
贝壳完成签到,获得积分10
刚刚
可燃乌龙茶完成签到 ,获得积分10
1秒前
1秒前
2秒前
房子发布了新的文献求助10
2秒前
worldpeace完成签到,获得积分10
3秒前
林林发布了新的文献求助10
3秒前
3秒前
嘻嘻哈哈的应助被云落采纳,获得10
3秒前
Akim的应助被hanxx采纳,获得10
4秒前
4秒前
华仔的应助被湖蓝色块采纳,获得10
4秒前
molihuakai的应助被斯文曼波采纳,获得10
5秒前
FFF完成签到,获得积分20
5秒前
dou完成签到 ,获得积分10
6秒前
风朝东发布了新的文献求助10
6秒前
充电宝的应助被呼呼采纳,获得10
6秒前
TFauthor发布了新的文献求助50
7秒前
小帅完成签到,获得积分10
7秒前
8秒前
dlsq发布了新的文献求助30
8秒前
sy发布了新的文献求助10
8秒前
ket的应助被本色风情采纳,获得10
8秒前
木木完成签到,获得积分10
9秒前
111发布了新的文献求助10
10秒前
11秒前
11秒前
12秒前
leizhengyu完成签到,获得积分10
12秒前
小石头发布了新的文献求助10
12秒前
12秒前
13秒前
cccsh完成签到 ,获得积分10
14秒前
15秒前
领导范儿的应助被奔跑的猫猫采纳,获得10
15秒前
SLL发布了新的文献求助10
16秒前
3277125325发布了新的文献求助10
16秒前
17秒前
17秒前
NexusExplorer的应助被饺子采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187918
求助须知:如何正确求助?哪些是违规求助? 9575850
关于积分的说明 21843829
捐赠科研通 7785760
什么是DOI,文献DOI怎么找? 3435128
关于科研通互助平台的介绍 2559501
邀请新用户注册赠送积分活动 2482027